newsfilter
← Latest News
GlobeNewswire·

New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026

  • Eisai Co., Ltd. & Biogen Inc. announced new three-year real-world findings from the LEADER study involving 560 patients across 13 U.S. clinical sites.
  • A pre-specified analysis showed LEQEMBI treatment resulted in a 76% lower rate of progression to moderate or severe Alzheimer's dementia compared to a matched natural history cohort.
  • Among 546 assessable patients after an average of 18 months, 81.1% remained stable (75.8%) or improved (5.3%) compared to baseline.
  • Statistical modeling estimated that 95.0% of the 560 patients would remain in the early stages of Alzheimer's disease through three years of treatment.
  • Real-world evidence indicated that 77% of patients with available amyloid PET data became amyloid-negative at a median follow-up of 18.1 months.
  • Treatment persistence was high, with 87.5% of all patients remaining on LEQEMBI at chart extraction, including 91.7% of those reaching 18 months of treatment.
  • Transition data showed 218 patients moved to once-every-four-weeks intravenous maintenance, while 64 patients transitioned to once-weekly subcutaneous maintenance therapy.
  • Safety data for subcutaneous maintenance showed no amyloid-related imaging abnormalities (ARIA) events, while isolated ARIA-H incidence was 0.5% during intravenous maintenance.
  • Clinical outcomes were consistent between sexes, with 79.3% of women & 83.3% of men reported as stable or improved.
  • LEADER safety findings aligned with the independent ALZ-NET registry, showing ARIA-E rates of 6.6% in LEADER vs. 6.3% in ALZ-NET.
  • A separate international meta-analysis of approximately 5,000 patients across 16 cohorts found pooled ARIA rates lower than those in the Clarity AD clinical trial.
  • Symptomatic ARIA was observed in 0.8% of patients in the international meta-analysis compared to 2.8% in Clarity AD.
  • The data were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston alongside the meta-analysis.
Company
Biogen Inc.
Keywords
Nasdaq:BIIB, Biogen Inc.